TY - JOUR
T1 - A molecular dynamics investigation of Mycobacterium tuberculosis prenyl synthases
T2 - Conformational flexibility and implications for computer-aided drug discovery
AU - Kim, Meekyum Olivia
AU - Feng, Xinxin
AU - Feixas, Ferran
AU - Zhu, Wei
AU - Lindert, Steffen
AU - Bogue, Shannon
AU - Sinko, William
AU - De Oliveira, César
AU - Rao, Guodong
AU - Oldfield, Eric
AU - McCammon, James Andrew
N1 - Publisher Copyright:
© 2014 John Wiley & Sons A/S.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - With the rise in antibiotic resistance, there is interest in discovering new drugs active against new targets. Here, we investigate the dynamic structures of three isoprenoid synthases from Mycobacterium tuberculosis using molecular dynamics (MD) methods with a view to discovering new drug leads. Two of the enzymes, cis-farnesyl diphosphate synthase (cis-FPPS) and cis-decaprenyl diphosphate synthase (cis-DPPS), are involved in bacterial cell wall biosynthesis, while the third, tuberculosinyl adenosine synthase (Rv3378c), is involved in virulence factor formation. The MD results for these three enzymes were then compared with previous results on undecaprenyl diphosphate synthase (UPPS) by means of active site volume fluctuation and principal component analyses. In addition, an analysis of the binding of prenyl diphosphates to cis-FPPS, cis-DPPS, and UPPS utilizing the new MD results is reported. We also screened libraries of inhibitors against cis-DPPS, finding ~1 μm inhibitors, and used the receiver operating characteristic-area under the curve (ROC-AUC) method to test the predictive power of X-ray and MD-derived cis-DPPS receptors. We found that one compound with potent M. tuberculosis cell growth inhibition activity was an IC50 ~0.5- to 20-μm inhibitor (depending on substrate) of cis-DPPS, a ~660-nm inhibitor of Rv3378c as well as a 4.8-μm inhibitor of cis-FPPS, opening up the possibility of multitarget inhibition involving both cell wall biosynthesis and virulence factor formation.
AB - With the rise in antibiotic resistance, there is interest in discovering new drugs active against new targets. Here, we investigate the dynamic structures of three isoprenoid synthases from Mycobacterium tuberculosis using molecular dynamics (MD) methods with a view to discovering new drug leads. Two of the enzymes, cis-farnesyl diphosphate synthase (cis-FPPS) and cis-decaprenyl diphosphate synthase (cis-DPPS), are involved in bacterial cell wall biosynthesis, while the third, tuberculosinyl adenosine synthase (Rv3378c), is involved in virulence factor formation. The MD results for these three enzymes were then compared with previous results on undecaprenyl diphosphate synthase (UPPS) by means of active site volume fluctuation and principal component analyses. In addition, an analysis of the binding of prenyl diphosphates to cis-FPPS, cis-DPPS, and UPPS utilizing the new MD results is reported. We also screened libraries of inhibitors against cis-DPPS, finding ~1 μm inhibitors, and used the receiver operating characteristic-area under the curve (ROC-AUC) method to test the predictive power of X-ray and MD-derived cis-DPPS receptors. We found that one compound with potent M. tuberculosis cell growth inhibition activity was an IC50 ~0.5- to 20-μm inhibitor (depending on substrate) of cis-DPPS, a ~660-nm inhibitor of Rv3378c as well as a 4.8-μm inhibitor of cis-FPPS, opening up the possibility of multitarget inhibition involving both cell wall biosynthesis and virulence factor formation.
KW - decaprenyl diphosphate synthase
KW - docking
KW - drug discovery
KW - enzymatic mechanism
KW - farnesyl diphosphate synthase
KW - molecular dynamics
KW - molecular modeling
KW - prenyl synthase
KW - tuberculosinyl adenosine synthase
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=84929301952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929301952&partnerID=8YFLogxK
U2 - 10.1111/cbdd.12463
DO - 10.1111/cbdd.12463
M3 - Article
C2 - 25352216
AN - SCOPUS:84929301952
SN - 1747-0277
VL - 85
SP - 756
EP - 769
JO - Chemical Biology and Drug Design
JF - Chemical Biology and Drug Design
IS - 6
ER -